Female Health FHCO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Female Health FHCO

VERU 2.340

+0.9%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	12/16/2025 7:45:09 PM
	of 213

Veru Inc. (NASDAQ: VERU) will release earnings results for i Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period. Raymond James analyst Gary Nachman maintained an Outperform rating and cut the price target from $30 to $20 on Aug. 13, 2025. This analyst has an accuracy rate of 62%. HC Wainwright & Co. analyst Yi Chen maintained a Buy rating with a price target of $3 on Jan. 2, 2025. This analyst has an accuracy rate of 66%. Oppenheimer analyst Leland Gershell maintained an Outperform rating with a price target of $5 on Nov. 5, 2024. This analyst has an accuracy rate of 75% Analysts expect the Miami, Florida-based company to report quarterly loss at 39 cents per share, versus a year-ago loss of 52 cents per share, according to Benzinga Pro. Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings - Veru (NASDAQ:VERU) - Benzinga

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next